Antiplatelet therapy: Do the new platelet inhibitors add significantly to the clinicl benefits of aspirin? - 10/09/11
Abstract |
The inhibitors of the platelet membrane glycoprotein IIb/IIIa show considerable promise as antiplatelet agents. These drugs are easily titrated when administered intravenously and are associated with less frequent and serious bleeding than initially feared. They add significant benefit to that attributable to aspirin in preventing the complications associated with coronary angioplasty. Pilot studies have suggested that benefits could also be realized in acute myocardial infarction and unstable angina. The most effective means of administering these agents, their relative efficacy, and the consequences of long-term modulation of the glycoprotein IIb/IIIa receptor by oral agents are challenging areas for clinical investigation. (Am Heart J 1997;134:S62-S70)
Il testo completo di questo articolo è disponibile in PDF.Mappa
 | Reprint requests: Pierre Théroux, MD, Montreal Heart Institute, 5000 Belanger St. E., Montreal, Quebec, Canada H1T 1C8. |
| 4/0/84741 |
Vol 134 - N° 5P2
P. s62-s70 - Novembre 1997 Ritorno al numero
Articolo precedente
- Triggering and the pathophysiology of acute coronary syndromes
- Geoffrey H. Tofler, From the Department of Medicine, Harvard Medical School, and the Institute for Prevention of Cardiovascular Disease, Beth Israel Deaconess Medical Center.
- Successors to heparin: New antithrombotic agents
- Alexander G.G. Turpie, From McMaster University, Hamilton Civic Hospitals.
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?